[Dabigatran in the treatment of a morbidly obese patient with recurring venous thrombosis].
Callejas Rubio
J L
JL
Lara Jiménez
M A
MA
Fernández Pugnaire
M A
MA
Ortego Centeno
N
N
D000074:Acenocoumarol / Q000009:adverse effects / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D057176:Compassionate Use Trials; D000069604:Dabigatran; D005260:Female; D006406:Hematoma / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009767:Obesity, Morbid / Q000150:complications*; D011725:Pyridines / Q000627:therapeutic use*; D012008:Recurrence; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology
D000925:Anticoagulants; D001562:Benzimidazoles; D006495:Heparin, Low-Molecular-Weight; D011725:Pyridines; D000069604:Dabigatran; D000074:Acenocoumarol; C411345:bemiparin
Dabigatran para el tratamiento de una paciente con obesidad mórbida y trombosis venosa recidivante.